Aptose provides TUS+VEN+AZA triplet clinical update and 2025 milestones

Aptose Biosciences Inc.

40mg TUS+VEN+AZA triplet achieved CRs in FLT3-WT and TP53-mutated newly diagnosed AML; no DLTs.
80mg TUS dose cohort in TUS+VEN+AZA triplet is currently enrolling.
Hanmi collaboration expected Q2 2025; $10M advance converting to common stock.
Raised approx. $37M in 2024; capital structure: 2.14M shares O/S, 1.27M warrants.
Planned data releases at EHA 2025 and ASH 2025; dose selection for Ph2/3 pivotal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.